Gilead Sciences, Inc. Stock price

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
73.26 USD -0.58% Intraday chart for Gilead Sciences, Inc. -2.73% -9.57%
Sales 2024 * 27.51B Sales 2025 * 28.03B Capitalization 91.27B
Net income 2024 * 6.54B Net income 2025 * 6.86B EV / Sales 2024 * 3.75 x
Net Debt 2024 * 11.84B Net Debt 2025 * 4.96B EV / Sales 2025 * 3.43 x
P/E ratio 2024 *
14.1 x
P/E ratio 2025 *
13.2 x
Employees 18,000
Yield 2024 *
4.28%
Yield 2025 *
4.47%
Free-Float 99.91%
More Fundamentals * Assessed data
Dynamic Chart
Gilead Sciences Receives a Shareholder Proposal from John Chevedden CI
Gilead Sciences Receives a Shareholder Proposal from David Bahnsen CI
Gilead Sciences Receives a Shareholder Proposal from Jing Zhao CI
Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024 CI
Transcript : Gilead Sciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Transcript : Gilead Sciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 10:00 AM
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires MT
Health Care Up as Sector Gathers Upward Momentum -- Health Care Roundup DJ
Merck, Gilead Sciences Report Positive Data From Phase 2 Trial of Islatravir, Lenacapavir Combination in HIV MT
Gilead, Merck Report Positive Phase 2 Data on Weekly Oral HIV Combo DJ
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 CI
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies MT
Gilead, Merus to Collaborate on Trispecific Antibody Research DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers CI
Gilead Sciences Says Study Results Back Use of Veklury for People With COVID-19 MT
More news
1 day-0.58%
1 week-2.73%
Current month+1.61%
1 month+2.35%
3 months-7.85%
6 months-3.12%
Current year-9.57%
More quotes
1 week
73.21
Extreme 73.205
76.18
1 month
71.45
Extreme 71.45
76.21
Current year
71.37
Extreme 71.37
87.87
1 year
71.37
Extreme 71.37
87.87
3 years
57.17
Extreme 57.165
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-02-28
Director of Finance/CFO 54 15-12-31
Chief Tech/Sci/R&D Officer - 21-04-11
Members of the board TitleAgeSince
Director/Board Member 69 20-10-16
Director/Board Member 71 17-12-31
Director/Board Member 65 Jan. 31
More insiders
Date Price Change Volume
24-03-18 73.26 -0.58% 6,937,786
24-03-15 73.69 -0.70% 13,963,774
24-03-14 74.21 -2.28% 8,399,270
24-03-13 75.94 +1.15% 6,003,025
24-03-12 75.08 -0.32% 7,056,289

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
73.26 USD
Average target price
86.45 USD
Spread / Average Target
+18.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq